Literature DB >> 22315131

Willingness to use tamoxifen to prevent breast cancer among diverse women.

Celia Patricia Kaplan1, Sue E Kim, Sabrina T Wong, George F Sawaya, Judith M E Walsh, Eliseo J Pérez-Stable.   

Abstract

Use of chemoprevention to prevent development of breast cancer among high-risk women has been limited despite clinical evidence of its benefit. Our goals were to determine whether knowledge of the benefits and risks of tamoxifen affects a woman's willingness to take it to prevent breast cancer, to define factors associated with willingness to take tamoxifen, and to evaluate race/ethnic differences. Women, ages 50-80, who identified as African American, Asian, Latina, or White, and who had at least one visit to a primary care physician in the previous 2 years, were recruited from ambulatory practices. After a screening telephone survey, women completed an in-person interview in their preferred language. Multivariate regression models were constructed to examine the associations of demographic characteristics, numeracy, breast cancer history, and health knowledge with willingness to take tamoxifen. Over 40% of the women reported they would likely take tamoxifen if determined to be at high risk, and 31% would be somewhat likely to do so. Asian women, those with no insurance, and those with less than high school education were significantly more likely to be willing to take tamoxifen. Higher scores on numeracy and on breast cancer knowledge were also associated with willingness to take tamoxifen. A higher tamoxifen knowledge score was inversely related to willingness to take the drug. Factors affecting women's willingness to take breast cancer chemoprevention drugs vary and are not determined solely by knowledge of risk/benefit or risk perception.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315131      PMCID: PMC4039196          DOI: 10.1007/s10549-012-1960-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer Assessment of Health Plans Study.

Authors:  L D Harris-Kojetin; F J Fowler; J A Brown; J A Schnaier; S F Sweeny
Journal:  Med Care       Date:  1999-03       Impact factor: 2.983

2.  Women's interest in chemoprevention for breast cancer.

Authors:  L A Bastian; I M Lipkus; M N Kuchibhatla; H H Weng; S Halabi; P D Ryan; C S Skinner; B K Rimer
Journal:  Arch Intern Med       Date:  2001-07-09

Review 3.  Breast cancer risk reduction: strategies for women at increased risk.

Authors:  Rowan T Chlebowski
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

4.  Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.

Authors:  Sharon L Bober; Lizbeth A Hoke; Rosemary B Duda; Meredith M Regan; Nadine M Tung
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

5.  Using visual displays to communicate risk of cancer to women from diverse race/ethnic backgrounds.

Authors:  Sabrina T Wong; Eliseo J Pérez-Stable; Sue E Kim; Steven E Gregorich; George F Sawaya; Judith M E Walsh; A Eugene Washington; Celia P Kaplan
Journal:  Patient Educ Couns       Date:  2012-01-12

6.  The role of numeracy in understanding the benefit of screening mammography.

Authors:  L M Schwartz; S Woloshin; W C Black; H G Welch
Journal:  Ann Intern Med       Date:  1997-12-01       Impact factor: 25.391

7.  Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Authors:  Joy Melnikow; Debora Paterniti; Rahman Azari; Christina Kuenneth; Stephen Birch; Miriam Kuppermann; James Nuovo; Janet Keyzer; Stuart Henderson
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

8.  Women's misconceptions about cancer screening: implications for informed decision-making.

Authors:  Thomas D Denberg; Sabrina Wong; Angela Beattie
Journal:  Patient Educ Couns       Date:  2005-06

9.  Acceptance of tamoxifen chemoprevention by physicians and women at risk.

Authors:  Julia Tchou; Nanjiang Hou; Alfred Rademaker; V Craig Jordan; Monica Morrow
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

10.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

View more
  17 in total

1.  Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1.

Authors:  Christine M Gunn; Barbara G Bokhour; Victoria A Parker; Tracy A Battaglia; Patricia A Parker; Angela Fagerlin; Worta McCaskill-Stevens; Hanna Bandos; Sarah B Blakeslee; Christine Holmberg
Journal:  Med Decis Making       Date:  2019-02-25       Impact factor: 2.583

2.  Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Authors:  Meghna S Trivedi; Austin M Coe; Alejandro Vanegas; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

3.  A randomized, controlled trial to increase discussion of breast cancer in primary care.

Authors:  Celia P Kaplan; Jennifer Livaudais-Toman; Jeffrey A Tice; Karla Kerlikowske; Steven E Gregorich; Eliseo J Pérez-Stable; Rena J Pasick; Alice Chen; Jessica Quinn; Leah S Karliner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-24       Impact factor: 4.254

4.  Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial.

Authors:  Jennifer Livaudais-Toman; Leah S Karliner; Jeffrey A Tice; Karla Kerlikowske; Steven Gregorich; Eliseo J Pérez-Stable; Rena J Pasick; Alice Chen; Jessica Quinn; Celia P Kaplan
Journal:  Breast       Date:  2015-10-21       Impact factor: 4.380

5.  Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

Authors:  Erika A Waters; Timothy S McNeel; Worta McCaskill Stevens; Andrew N Freedman
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

6.  What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?

Authors:  Kathryn A Martinez; Angela Fagerlin; Holly O Witteman; Christine Holmberg; Sarah T Hawley
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

7.  Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk
Journal:  Breast       Date:  2014-12-06       Impact factor: 4.380

8.  Colorectal cancer screening: what do women from diverse ethnic groups want?

Authors:  Judith M E Walsh; Sue E Kim; George Sawaya; Celia P Kaplan; Sabrina T Wong; Steve E Gregorich; Eliseo J Pérez-Stable
Journal:  J Gen Intern Med       Date:  2012-09-12       Impact factor: 5.128

Review 9.  Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.

Authors:  Andrea DeCensi; Mangesh A Thorat; Bernardo Bonanni; Samuel G Smith; Jack Cuzick
Journal:  Ecancermedicalscience       Date:  2015-11-24

Review 10.  Tamoxifen for women at high risk of breast cancer.

Authors:  Safia A Nazarali; Steven A Narod
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.